Thrust & Parry: CVT And Gilead Look To Lock Out Astellas With Planned Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead’s surprise $20 per share bid tops Astellas’ $16 per share offer, highlights Gilead’s increasing focus on cardiovascular space.
You may also be interested in...
Astellas Takes Hostile $3.5 Bil. Bid To OSI Shareholders
To publicize its hostile bid for OSI Pharmaceuticals, Astellas Pharma has registered the Web site oncologyleader.com. Call it hopefulness, call it hubris, but in the race to build an oncology business, Astellas is as far back in the pack as a 14,000-person global pharmaceutical firm can be
Astellas Takes Hostile $3.5 Bil. Bid To OSI Shareholders
To publicize its hostile bid for OSI Pharmaceuticals, Astellas Pharma has registered the Web site oncologyleader.com. Call it hopefulness, call it hubris, but in the race to build an oncology business, Astellas is as far back in the pack as a 14,000-person global pharmaceutical firm can be
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Japan's second-biggest pharma offers $3.5 billion to OSI shareholders after 13 months of rejection by the target's management.